AstraZeneca Report Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Acute Ischemic Stroke or Transient Ischemic Attack

Shots:

• The P-III THALES study involves assessing of Brilinta (180mg as a loading dose followed by 90mg, bid) + aspirin vs aspirin as monothx. in 11,000 patients with non-cardioembolic acute ischaemic stroke or high-risk TIA for 30days
• Results: 17% reduction in 1EPs of stroke and death, 21% reduction in 2EPs of ischaemic stroke, the risk for severe bleeding events (0.1% vs 0.5%); results were consistent with the known safety profile of Brilinta
• Brilinta is approved in 110+ countries to prevent atherothrombotic events in adult patients with ACS and in 70+ countries for the secondary prevention of CV events among high-risk patients experienced a heart attack. In May’2020, the FDA approved a label update for Brilinta in the US to include the reduction of the risk of a first heart attack or stroke in high-risk patients with CAD

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: CNBC